全文获取类型
收费全文 | 176777篇 |
免费 | 13594篇 |
国内免费 | 4257篇 |
专业分类
耳鼻咽喉 | 2110篇 |
儿科学 | 9201篇 |
妇产科学 | 4620篇 |
基础医学 | 20347篇 |
口腔科学 | 2377篇 |
临床医学 | 17258篇 |
内科学 | 30140篇 |
皮肤病学 | 3268篇 |
神经病学 | 24440篇 |
特种医学 | 3989篇 |
外国民族医学 | 13篇 |
外科学 | 15860篇 |
综合类 | 20165篇 |
现状与发展 | 17篇 |
一般理论 | 4篇 |
预防医学 | 10124篇 |
眼科学 | 3111篇 |
药学 | 10934篇 |
64篇 | |
中国医学 | 12831篇 |
肿瘤学 | 3755篇 |
出版年
2024年 | 325篇 |
2023年 | 3135篇 |
2022年 | 4704篇 |
2021年 | 8855篇 |
2020年 | 7984篇 |
2019年 | 7566篇 |
2018年 | 7411篇 |
2017年 | 7022篇 |
2016年 | 6513篇 |
2015年 | 6289篇 |
2014年 | 12592篇 |
2013年 | 14187篇 |
2012年 | 10250篇 |
2011年 | 11397篇 |
2010年 | 8755篇 |
2009年 | 8382篇 |
2008年 | 8063篇 |
2007年 | 7686篇 |
2006年 | 6793篇 |
2005年 | 5596篇 |
2004年 | 5001篇 |
2003年 | 4392篇 |
2002年 | 3089篇 |
2001年 | 2738篇 |
2000年 | 2453篇 |
1999年 | 2187篇 |
1998年 | 1837篇 |
1997年 | 1772篇 |
1996年 | 1572篇 |
1995年 | 1446篇 |
1994年 | 1257篇 |
1993年 | 1136篇 |
1992年 | 987篇 |
1991年 | 797篇 |
1990年 | 725篇 |
1989年 | 609篇 |
1988年 | 586篇 |
1987年 | 526篇 |
1986年 | 448篇 |
1985年 | 1107篇 |
1984年 | 1099篇 |
1983年 | 720篇 |
1982年 | 865篇 |
1981年 | 755篇 |
1980年 | 618篇 |
1979年 | 562篇 |
1978年 | 429篇 |
1977年 | 331篇 |
1976年 | 296篇 |
1975年 | 270篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
101.
102.
103.
104.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
105.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
106.
107.
108.
Salvatore Greco Beatrice Bonsi Nicol Fabbri 《World Journal of Experimental Medicine》2022,12(5):104-107
Even if the relationships between nutrition and inflammatory bowel disease (IBD) remain underexplored, the current literature is providing, day by day, much more evidence on the effects of various diets in both prevention and treatment of such illnesses. Wrong dietary habits, together with other environmental factors such as pollution, breastfeeding, smoke, and/or antibiotics, are among the theoretical pathogenetic causes of IBD, whose multifactorial aetiology has been already confirmed. While some of these risk factors are potentially reversible, some others cannot be avoided, and efficient treatments become necessary to prevent IBD spread or recurrence. Furthermore, the drugs currently available for treatment of such disease provide low-to-no effect against the symptoms, making the illnesses still strongly disabling. Whether nutrition and specific diets will prove to effectively interrupt the course of IBD has still to be clarified and, in this sense, further research concerning the applications of such dietary interventions is still needed. 相似文献
109.
目的 探讨糖尿病前期的中医证型及证素分布特点。方法 检索中国知网、万方及维普三大数据库中收录的自建库以来有关糖尿病前期证型的临床研究文献,对中医证型进行规范整理,建立数据库,提取证素,运用数据挖掘技术中的关联分析、聚类分析探究证素分布规律。结果 共纳入10篇文献,总有效病例1620例,证型经规范处理后整理为18个,主要证型为脾虚痰湿证。共提取证素13个,主要病位证素为脾,主要病性证素为气虚、湿和痰,关联分析显示脾—湿支持度和置信度最高,聚类分析结果可得到3个聚类组。结论 糖尿病前期病位在脾,气虚、脾、痰、湿是常见证素,临床诊治糖尿病前期应注重从脾论治,需辨证施治。 相似文献
110.